about
EVI1 activation in blast crisis CML due to juxtaposition to the rare 17q22 partner region as part of a 4-way variant translocation t(9;22).Bosutinib efficacy and safety in chronic phase chronic myeloid leukemia after imatinib resistance or intolerance: Minimum 24-month follow-up.Long-term bosutinib for chronic phase chronic myeloid leukemia after failure of imatinib plus dasatinib and/or nilotinib.Small interfering RNA against BCR-ABL transcripts sensitize mutated T315I cells to nilotinibCCC meets ICU: redefining the role of critical care of cancer patients.Imatinib: a breakthrough of targeted therapy in cancer.Kinase domain point mutations in Philadelphia chromosome-positive acute lymphoblastic leukemia emerge after therapy with BCR-ABL kinase inhibitors.Monitoring response and resistance to treatment in chronic myeloid leukemia.Expression of EBV encoded viral RNA 1, 2 and anti-inflammatory cytokine (interleukin-10) in FFPE lymphoma specimens: a preliminary study for diagnostic implication in PakistanUnbiased functional proteomics strategy for protein kinase inhibitor validation and identification of bona fide protein kinase substrates: application to identification of EEF1D as a substrate for CK2.Role of exosomes released by chronic myelogenous leukemia cells in angiogenesis.Bosutinib is active in chronic phase chronic myeloid leukemia after imatinib and dasatinib and/or nilotinib therapy failureCML patients in the molecular era - report of five years experience of diagnosis and treatment in a single centerCurrent management of chronic myeloid leukemia with tyrosine kinase inhibitors.Tyrosine kinase gene rearrangements in epithelial malignancies.Targeting the BCR-ABL tyrosine kinase in chronic myeloid leukemia as a model of rational drug design in cancer.Towards clinical applications of selected reaction monitoring for plasma protein biomarker studies.New mutation L324M in the ABL1 kinase domain: does it confer high resistance to second-generation inhibitors?Lack of congruence between patients' and health professionals' perspectives of adherence to imatinib therapy in treatment of chronic myeloid leukemia: A qualitative study
P2860
Q33350395-0D5F1883-0F8A-44F7-B7E7-6BBFE316DC83Q33414487-3B471E2D-E159-48E9-A1FB-D031A18E9476Q33434675-BC5B2C2E-4436-4362-958D-C618FE923C47Q33707394-7F0E2BFF-43B3-4809-A24A-5045EDC776C1Q33741056-206BA0D2-771D-403C-B414-A3BAE918B6FDQ33747261-AC973BDD-43A8-49F3-AE9D-82BC035DD7C0Q34378360-7DC2041B-D854-4B80-909A-C7CE87D4F77FQ34761663-E0D366B7-F3C1-4B76-8A07-642F0BD8661FQ35168623-AD87EA66-ADD6-4410-8AD5-3119DA49D198Q35526322-9873CF54-A862-47CD-84F7-FFF28BEE01F7Q35608487-0B9A308C-DDB2-425C-8239-B3FCFFFF8F83Q37027759-245AB318-0DB4-444B-B743-1D42514F28B3Q37206193-CAEB2F90-5C7D-4CD4-B4DC-BEDB876A62E1Q37426573-7202737F-02DE-48EF-9D6B-82AFABA58989Q37515966-7AD54828-B258-4553-8632-D2B80BB6B5E6Q37810070-1457E458-5287-4788-B986-1F65BBDF915EQ37972865-25AEF08F-5B1A-4CC5-8B41-750411271AE3Q50931856-B1E75154-FC22-46B8-869B-4BA5C246F2DEQ57143102-E4A4B2C3-1B64-43FA-9D43-1B00D6DB5708
P2860
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on January 2008
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Targeted therapy in chronic myeloid leukemia.
@en
Targeted therapy in chronic myeloid leukemia.
@nl
type
label
Targeted therapy in chronic myeloid leukemia.
@en
Targeted therapy in chronic myeloid leukemia.
@nl
prefLabel
Targeted therapy in chronic myeloid leukemia.
@en
Targeted therapy in chronic myeloid leukemia.
@nl
P2860
P50
P356
P1476
Targeted therapy in chronic myeloid leukemia.
@en
P2093
Hady Ghanem
P2860
P304
P356
10.1586/14737140.8.1.99
P577
2008-01-01T00:00:00Z